[CAS NO. 1402837-78-8] Navoximod
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1402837-78-8]
Store
Catalog
SLK-S8957
Brand
Selleck
CAS
1402837-78-8
DESCRIPTION [1402837-78-8]
Overview
| MDL | MFCD29472253 |
|---|---|
| Molecular Weight | 316.37 |
| Molecular Formula | C18H21FN2O2 |
| SMILES | O[C@H](CC1)CC[C@]1([H])[C@H](O)C[C@@H]2N3C(C4=C2C(F)=CC=C4)=CN=C3 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1609 mL | 15.8043 mL | 31.6086 mL |
| 5 mM | 0.6322 mL | 3.1609 mL | 6.3217 mL |
| 10 mM | 0.3161 mL | 1.5804 mL | 3.1609 mL |
| 50 mM | 0.0632 mL | 0.3161 mL | 0.6322 mL |
Description
Navoximod (GDC-0919, NLG-919) is a potent inhibitor of pathway with Ki of 7 nM and EC50 of 75 nM.
In vitro
NLG919 potently blocks IDO-induced T-cell suppression and restored robust T-cell responses with ED50 of 80 nM. Similarly, using IDO-expressing mouse DCs from tumor-draining lymph nodes, NLG919 abrogated IDO-induced suppression of antigen-specific T cells (OT-I) in vitro, with ED50 of 120 nM. NLG919 increases the cytotoxic activity of paclitaxel toward B16-F10 cells in the presence of pretreatment with interferon (IFN)-γ in vitro.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.